Bollard Group’s Heron Therapeutics HRTX Stock Holding History

Bollard Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-956	Closed	-$1K	–	516
2023 Q2	$1K	Buy	+956	New	+$1.71K	﹤0.01%	602

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Bollard Group's HRTX Position: Q3 2023 in Review

Bollard Group sold out of Heron Therapeutics (HRTX) in Q3 2023, closing a stake of 956 shares — an estimated $1K sold.

Bollard Group first reported a position in HRTX in Q2 2023 and held it in 1 quarter. The position peaked at $1K in Q2 2023. 141 funds tracked by Wall St. Rank hold HRTX as of Q3 2023.

Bollard Group reported no remaining Heron Therapeutics position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 956 Heron Therapeutics shares in Q3 2023, an estimated $1K.
Bollard Group first reported a position in Heron Therapeutics in Q2 2023 and held it in 1 quarter.
Bollard Group's Heron Therapeutics position peaked at $1K in Q2 2023.
141 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.